Crossmark

Mixed-method evaluation study of a targeted mass drug administration of long-acting anti-malarials among children aged 3 months to 15 years in the Bossangoa sub-prefecture, Ouham, Central African Republic, during the COVID-19 pandemic

Crossref DOI link: https://doi.org/10.1186/s12936-024-04968-1

Published Online: 2024-05-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Robinson, Eve

Ouabo, Adelaide

Rose, Letitia

van Braak, Felipe

Vyncke, Jorieke

Wright, Roberto

Gray, Nell

Sakama, Narcisse Simon

Aboukar, Emmanuel Joao

Fierte, Methode Mberyo

Woinzoukou, Daniel

Ewers, Linn

Serpande, Christian

Stein, Susanne

Van Boetzelaer, Elburg

Kpahina, Odilon Auguste

Sabe, Sosthene Constant

Rao, Bhargavi

Kuehne, Anna
License Information

Text and Data Mining valid from 2024-05-15

Version of Record valid from 2024-05-15
More Information

Article History

Received: 22 December 2023

Accepted: 29 April 2024

First Online: 15 May 2024

Declarations

:

: Ethical approval for the evaluation study was granted by the MSF Ethics Review Board (ERB) (Protocol ID:2057; approved 29 September 2020), and the national ERB of CAR—<i>Comité Scientifique charge de la validation des protocols d’étude et des résultats, Université de Bangui, Faculté de Science de la Santé</i> (approved 3 November 2020).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below